Veterinary Cooperative Oncology Group Common Terminology Criteria for Adverse Events (VCOG-CTCAE) v.1.1. 4 Management of AE involves administration of concomitant medications and changes to the dosage, frequency, or both factors of drug administration. In some cases, discontinuation of toceranib is required to manage AE or is requested by the owner because of impact on quality of life of the dogs.
The impact of changes to dose intensity and treatment withdrawal on outcome for dogs receiving toceranib has not been evaluated to the author's knowledge. In people with renal cell carcinoma receiving sunitinib, changes to dose, frequency, or both lead to reduced response rates, progression free survival, and overall survival. 5 Thus, the ability to identify patients at risk for the development of GI AEs could allow for early intervention of preventative treatments thereby reducing the need for dose reductions or delays.
Recently, the detection of cytokeratin 18 (CK18) in the plasma of people treated with chemotherapy for lymphoma was demonstrated as a clinically relevant biomarker for the early detection of signs of GI toxicosis. 6 Plasma CK18 concentrations are higher in patients who experience higher grade GI toxicosis than those who do not. 6 This finding suggests that plasma CK18 could represent a clinically useful biomarker to predict patient populations at risk for chemotherapyassociated toxicosis and identify patients that could benefit from more aggressive preventative treatment.
CK18 is a member of the intermediate filament family of cytoskel-
etal proteins expressed in epithelial cells. 7, 8 It compromises approximately 5% of total protein content in epithelial tissues including liver, exocrine pancreas, and the GI tract. 9 During apoptosis, caspasecleaved CK18 fragments are released into the extracellular space. 10 Therefore, the presence of CK18 fragments in plasma can be utilized as a biomarker for epithelial cell apoptosis. [6] [7] [8] [10] [11] [12] Cellular stress, such as that caused by anticancer drugs, results in the activation of the intrinsic apoptotic pathway and eventual activation of downstream effector caspases 3 and 7. 7, 13 These caspases cleave a variety of substrates including CK18. 8, 9 The primary objective of this study was to evaluate the feasibility of measuring plasma CK18 concentrations in healthy dogs and dogs being treated with toceranib for MCT, and if CK18 concentrations in dogs receiving toceranib correlated with the development of GI AE. We hypothesized that dogs receiving toceranib would have higher CK18 concentrations at the conclusion of the study period compared with the healthy controls, and CK18 concentrations would increase from baseline in dogs that developed GI AE.
| MATERIALS AND METHODS

| Study design
This study was designed as a prospective cohort study. 
| Study schedule
The day that toceranib was started was considered day 0. A physical examination, body weight, collection of 6 mL of blood for plasma CK18 
| Statistical analysis
A two-sample t test with equal variance was used to assess the mean difference in demographic variables (age and sex) and plasma CK18
concentrations between cases and controls. A multivariable mixed logistic regression was used to assess differences in the odds of a case developing signs of GI toxicosis. The main fixed effect variable of interest was average plasma CK18 values for each case. We utilized a risk factor modeling approach and included drug dose (mg/kg), breed, categorized as small, large or mix breed, sex, and age in the model as fixed effects to control for potential confounding. Drug dose and age were continuous variables, and sex and breed were categorical variables. The individual dog was included in this model as a random effect.
Two generalized linear mixed models were used to assess the potential association of plasma CK18 and VEGF blood concentrations with visit week among cases. Normality of the outcome variables was assessed using standard graphical methods. 14 3 | RESULTS
| Dogs
Twenty healthy controls and 25 dogs with MCTs were enrolled (Table 1 ). There were no significant differences between the dogs with MCTs and the controls in age, sex, or body weight (P = 0.17, 0.099, and 0.44, respectively). Twenty-one dogs completed the study. Four dogs were withdrawn from the study for a variety of reasons. Three dogs withdrew after 1 week, whereas one dog withdrew after 1 weeks.
The 1st Table 2 .
Greater than 95% of the AE were grade 1 or 2. Drug holidays occurred in 2 dogs, of which 1 dog also had a dose adjustment. One dog had a 1-week drug holiday for grade 2 diarrhea. Toceranib was restarted at the same dose and frequency without recurrence of diarrhea. The 2nd dog had a 1-week drug holiday for grade 2 diarrhea and grade 3 anorexia. The dog's dose was reduced from 2.87 mg/kg PO q48h to 2.47 mg/kg PO Monday, Wednesday, and Fridays. However, the dog's diarrhea and inappetence recurred after 2 weeks at this dose so toceranib was discontinued. The most common group of AE was GI, accounting for 53% (34 events) of all reported AE. Diarrhea (50%)
was the most common GI AE, followed by vomiting (29%), nausea (12%), and anorexia (8%). The second most common group of AE was hematological, accounting for 11% (7 events). Neutropenia (5 events) was the most common followed by one episode each of lymphocytosis and anemia.
| CK 18
Plasma CK18 was measured in the 20 control dogs and in 25 MCT dogs at baseline (day 0 (0-2368.86 pg/mL). There was no statistically significant difference in plasma CK18 between the control dogs and the MCT dogs at day 0 (P = 0.27) (Figure 1 ) or day 28 (P = 0.21). Plasma CK18 concentrations at day 0 in the MCT dogs were significantly higher (P < 0.001) compared to concentrations at day 28 (313.54 AE 118.55 and 244.37 AE 112.63, respectively). The average plasma CK18 among cases on day 28 was 98.69 pg/mL less than the average on day 0 (P < 0.001). The most significant decrease in plasma CK18 concentrations occurred between day 0 and day 7 (P < 0.003) (Figure 2 ). The average plasma CK18 among cases at day 7 was 50.8 pg/mL less than the average on day 0. Plasma CK18 concentration was not a significant predictor of the development of signs of GI toxicoses.
| VEGF
Plasma VEGF concentration was measured in 21 MCT dogs at day 0 and day 28. The mean (range) VEGF concentration at day 0 was 16.23 pg/ mL (2.745-114.94 pg/mL), and 106.39 pg/mL (7.472-929.61 pg/mL) at day 28. Mean VEGF concentration at day 28 was significantly higher than concentration at day 0 (P = 0.022) (Figure 3 ). (10) Rottweiler (2) Boxer (4) German shepherd (2) Labrador retriever (2) Golden retriever (2) Beagle (1) Lhasa Apso (1) Cocker spaniel (1) Staffordshire terrier (1) English bulldog (1) English setter (1) German shorthair pointer (1) Boxer (1) Newfoundland (1) German wirehair pointer (1) Staffordshire terrier (1) Poodle (1) Pug (1) St. Bernard (1) ITD, internal tandem duplication. These findings could have resulted from several factors. In all, 88% of study dogs experienced AE and over half of AE were GI. However, only 2 were grade 3 AE and no grade 4 GI AE occurred. This low incidence of higher grade GI AE could have limited the ability to detect a difference between dogs experiencing signs of GI disease and those that did not. Furthermore, the mechanism of toceranib-induced GI AE is not well understood and might not correlate with plasma CK18
concentrations.
We chose to evaluate plasma CK18 in dogs receiving toceranib, because of the high reported incidence of GI toxicosis including vomiting, diarrhea, and anorexia. A total of 20.7% of dogs receiving As opposed to other studies evaluating toceranib in MCTs, dogs could not be enrolled into our study if they had macroscopic primary or metastatic disease. This was done to avoid the confounding impact of development of signs of GI disease secondary to mast cell disease on the assessment of plasma CK18 and toceranib-related toxicity.
Dogs with macroscopic or metastatic disease are much more likely to develop clinical signs such as vomiting and diarrhea secondary to the release of mast cell mediators. 15 The incidence of GI ulceration is 35%-83% of dogs with MCTs examined at necropsy. 16, 17 Although the cause of ulceration in these dogs is likely multifactorial, the release of histamine from the tumor cells and the subsequent increase in production of hydrochloric acid from the parietal cells in the stomach is the primary cause. Dogs with macroscopic MCTs have higher plasma histamine concentrations than dogs with only microscopic disease, contributing to the higher incidence of related clinical signs. 18 We did not find any correlation between plasma CK18 concentrations and the development of signs of GI toxicosis. Analysis of correlation between grade of toxicosis and plasma CK18 was not performed because of low incidence of high grade GI toxicosis. The lack of correlation between CK18 concentrations and signs of GI toxicosis in our study might have been because of the following factors; the low number of dogs experiencing grade 3 and 4 toxicoses, the mechanism of toceranib-induced GI toxicosis, and the potential impact of toceranib on signaling mechanisms that influence intracellular concentrations of CK18.
Human studies utilizing plasma CK18 concentrations as a predictor of signs of GI toxicosis saw a significant difference when comparing patients with a grade 3 or higher toxicosis to those who experienced no or lower grade toxicoses. 6, 19 In these studies, plasma CK18 concentrations peaked 3 days after administration of traditional cytotoxic chemotherapeutic agents. Plasma CK18 concentrations at day 3 also gave the greatest power to identify patients experiencing the worst toxicoses. 6 Furthermore, patients with more severe toxicoses experienced higher and more durable peaks in plasma CK18 concentrations. 6 In contrast to these studies, few high-grade toxicoses developed in our study. Only 3 dogs developed a grade 3 or higher toxicosis, and of these, only 1 was considered GI in nature. This precluded analysis based on grade of toxicosis, potentially impacting the ability to identify a relationship between plasma CK18 and signs of GI toxicosis.
In the human studies assessing plasma CK18 as a biomarker for signs of GI toxicosis, subjects received traditional cytotoxic chemotherapeutic agents. 6, 19 These included doxorubicin, bleomycin, vinblastine, dacarbazine, cyclophosphamide, and vincristine. The administration of cytotoxic chemotherapy induces apoptosis of the intestinal crypts and can eventually result in crypt hypoplasia. 20, 21 These changes lead to the development of mucositis and diarrhea in patients receiving chemotherapy. During apoptosis, these cells release caspase-cleaved CK18 into the extracellular space, which is measurable in plasma, thus making plasma CK18 an effective biomarker for the identification of signs of GI toxicosis secondary to cytotoxic chemotherapy administration.
In contrast, the mechanism of GI toxicosis secondary to administration of TKIs such as toceranib is not well understood. In humans receiving TKIs, diarrhea is a commonly encountered side effect impacting treatment outcome as well as patient quality of life. Phase III studies of sunitinib for the treatment of metastatic renal cell carcinoma and GI stromal tumors have found that 29%-53% of patients experience diarrhea, with most being grade 1 or 2 in severity. 22 Other signs of GI disease reported less frequently include, vomiting, nausea, and constipation. 23, 24 Antiangiogenic TKIs such as those inhibiting vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) appear to have a higher reported incidence of diarrhea in the human literature compared with nonangiogenic TKIs. 25 This might suggest a possible relationship between angiogenic signaling inhibition and the development of diarrhea. 26 VEGF and EGFR are important for maintaining mucosal homeostasis and epithelialization after mucosal damage. Thus, it has been hypothesized that VEGFR and EGFR inhibition might lead to disruption in GI mucosa homeostasis and healing capabilities resulting in signs of GI toxicosis, particularly diarrhea. 27 To evaluate this, studies have been conducted in mouse and rat models of TKI-induced diarrhea. A rat model evaluating lapatinibinduced diarrhea found 81% of the rats developed diarrhea, with 67% developing moderately severe diarrhea. At necropsy, no significant lesions were detected within the GI tract. 28 In a mouse model receiving gefitinib, after 10 days of administration every 12 hours, the mice receiving genitinib had a significant decrease in the weight of the small and large intestines, and in the absorptive surface area of the intestines because of pronounced villi atrophy compared to the control population. 29 Both of these studies suggest that the development of diarrhea in patients receiving antiangiogenic TKIs is likely not because of direct mucosal damage through apoptosis as seen with the administration of cytotoxic chemotherapy drugs.
Other potential mechanisms of GI toxicosis caused by toceranib might be inhibition of c-KIT on interstitial cells of Cajal, the pacemaker cells of the intestine. 30 Alterations to these cells and their function might impact intestinal contractions leading to altered intestinal motility and the development of diarrhea. As we did not see any correlation between CK18 concentrations and signs of GI toxicity in our study, we suggest that toceranib induced diarrhea is likely not occurring because of apoptosis of the intestinal epithelial cells as described with cytotoxic chemotherapy drug administration.
Interestingly, we observed a decline in plasma CK18 concentrations over the study period with concentrations significantly lower in dogs at day 28 compared with day 0. The greatest decrease occurred between days 0 and 7. There is evidence that the role of CK18 within the body is more complex than solely in structural support. 31, 32 Relationships among CK18 and the phosphoinositide 3-kinase/protein kinase B (PI3K/AKT), Wnt, and mitogen activated protein 3 kinase (MAP3K) signaling pathways have been found. 31, 32 Thus, the decrease observed in CK18 over time might be related to downstream target inhibition by toceranib, the mechanism for which is not yet understood. These pathways play an important function in normal cell function, and in tumor cell survival, proliferation, and migration. In epithelial cancer cell lines, overexpression of AKT upregulated CK18 expression. 33 Additionally, blocking the ERK MAPK signaling pathway in Sertoli cells leads to inhibition of the CK18 expression. 34 However, studies have not assessed how TKIs, such as toceranib, impact these signaling processes in normal epithelial cells. Because of the complexity and interrelationship of these signaling pathways, the downstream effects of target inhibition by toceranib might impact CK18 concentrations within the cell, leading to an overall reduction of CK18 expression in epithelial cells. In turn, if intracellular concentrations of CK18 were reduced, these changes could potentially lead to a decrease in the CK18 released by cells undergoing apoptosis, which would be reflected in a decline in plasma CK18 concentrations. Therefore, this offers one potential cause for the decline appreciated in the dogs receiving toceranib in this study.
We demonstrated that the evaluation of CK18 in the plasma of dogs was possible. We did not detect a relationship between CK18
concentrations and the development of signs of GI toxicosis in dogs receiving toceranib as adjuvant treatment for surgically excised MCTs.
This finding might suggest that intestinal epithelial cell apoptosis is not the cause of toceranib-induced GI toxicosis in dogs, and further investigation is required to determine the mechanism responsible.
Additionally, in order to determine if plasma CK18 concentrations could be an effective biomarker for the early detection of antineoplastic drug-induced GI toxicosis, studies are ongoing evaluating its use in dogs receiving cytotoxic chemotherapeutic drugs. 
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